Yahoo! Video requires a more recent version of the Adobe Flash Player.
From
Published 36 months ago
Produced for Novartis - Statistics: According to the National Parkinson Foundation (NPF), dementia is one of the complications most feared by Parkinson’s disease patients and caregivers. Of the 1.5 million Americans living with the disease, an... more
Produced for Novartis - Statistics: According to the National Parkinson Foundation (NPF), dementia is one of the complications most feared by Parkinson’s disease patients and caregivers. Of the 1.5 million Americans living with the disease, an estimated 40% develop dementia. Story: The U.S. Food and Drug Administration (FDA) has approved Exelon (rivastigmine tartrate) for the treatment of mild to moderate Parkinson’s disease dementia, making it the first approved medication available for the treatment of this condition. The risk of developing dementia is approximately four to six times higher among Parkinson’s patients than among elderly people without the disease. The primary symptoms of Parkinson’s disease dementia include cognitive impairment and neuro-psychiatric symptoms (e.g., depression, hallucinations, anxiety and apathy). These symptoms impact the patient’s quality of life, course of the disease and caregiver distress. less
Tell us what you think about Yahoo! Video - Send us your feedback
Copyright © 2010 Yahoo! Inc. All rights reserved.
Comments (0)
LOADING
Add a new comment
Your reply